Table 1.
Characteristics of the study patients.
| PATIENT | AGE (YO) | GENDER | DISEASE DURATION (YR) | MEDICATIONS | COMORBIDITIES | Δ CRP | % Δ DAS28 |
|---|---|---|---|---|---|---|---|
| 1 | 61 | F | 0.5 | Meloxicam, MTX, prednisone, tramadol | Osteoarthritis | +1.12 | −16 |
| 2 | 42 | M | 8 | Hydroxychloroquine, MTX, prednisone, sulfasalazine, tramadol | – | −2.27 | −30 |
| 3 | 64 | F | 7 | Etanercept*, hydroxychloroquine, MTX, prednisone | – | +6.00 | −37 |
| 4 | 28 | F | 1 | MTX | Depression | −8.00 | −38 |
| 5 | 39 | F | 6 | MTX, prednisone | – | −23.00 | −60 |
| 6 | 21 | F | 0.5 | Meloxicam, MTX, prednisone, tramadol | Osteoarthritis learning disability | +10.00 | −17 |
| 7 | 46 | F | 19 | Etanercept*, MTX, naproxen, prednisone, tramadol | – | −25.00 | −18 |
| 8 | 71 | F | 17 | Adalimumab*, etanercept*, hydroxychloroquine, MTX, prednisone | Hyperlipidemia scoliosis congenital spondylolisthesis obstructive sleep apnea chronic peripheral venous insufficiency osteopenia osteoarthritis peripheral neuropathy | −1.00 | −51 |
| 9 | 46 | F | 19 | Etanercept*, MTX, naproxen, prednisone, tramadol | – | −25.00 | −18 |
| 10 | 55 | M | 17 | Prednisone | Hyperlipidemia | +3.00 | −15 |
Note:
*
Prior use.
Abbreviations: CRP, C-reactive protein; DAS28, Disease Activity Score 28; MTX, methotrexate.